- Home
- IKT vs CGTX Comparison
IKT vs CGTX Comparison
Compare IKT & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IKT | CGTX |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.9M | 158.8M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IKT | CGTX |
|---|---|---|
| Price | $1.54 | $1.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $4.00 | $2.88 |
| AVG Volume (30 Days) | 428.3K | ★ 942.9K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $0.22 |
| 52 Week High | $4.20 | $3.83 |
Technical Indicators
Market Signals| Indicator | IKT | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 53.10 |
| Support Level | $1.43 | $1.69 |
| Resistance Level | $1.57 | $1.77 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 73.81 | 75.58 |
Price Performance
Historical ComparisonAbout IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.